These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 8759939

  • 1. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma.
    Carr ME, Dent RM, Carr SL.
    J Lab Clin Med; 1996 Jul; 128(1):83-8. PubMed ID: 8759939
    [Abstract] [Full Text] [Related]

  • 2. Effects of ionic and nonionic contrast media on clot structure, platelet function and thrombolysis mediated by tissue plasminogen activator in plasma clots.
    Carr ME, Carr SL, Merten SR.
    Haemostasis; 1995 Jul; 25(4):172-81. PubMed ID: 7557656
    [Abstract] [Full Text] [Related]

  • 3. Effects of poloxamer 188 on the assembly, structure and dissolution of fibrin clots.
    Carr ME, Powers PL, Jones MR.
    Thromb Haemost; 1991 Nov 01; 66(5):565-8. PubMed ID: 1803621
    [Abstract] [Full Text] [Related]

  • 4. Effects of poloxamer 407 on the assembly, structure and dissolution of fibrin clots.
    Carr ME, Carr SL, High AA.
    Blood Coagul Fibrinolysis; 1996 Mar 01; 7(2):109-13. PubMed ID: 8735798
    [Abstract] [Full Text] [Related]

  • 5. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications.
    Undas A, Zubkiewicz-Usnarska L, Helbig G, Woszczyk D, Kozińska J, Dmoszyńska A, Dębski J, Podolak-Dawidziak M, Kuliczkowski K.
    Blood Coagul Fibrinolysis; 2015 Sep 01; 26(6):621-7. PubMed ID: 26083985
    [Abstract] [Full Text] [Related]

  • 6. Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma.
    Carr ME, Zekert SL.
    Am J Physiol; 1994 Mar 01; 266(3 Pt 2):H1195-201. PubMed ID: 8160823
    [Abstract] [Full Text] [Related]

  • 7. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis.
    Meh DA, Mosesson MW, DiOrio JP, Siebenlist KR, Hernandez I, Amrani DL, Stojanovich L.
    Blood Coagul Fibrinolysis; 2001 Dec 01; 12(8):627-37. PubMed ID: 11734662
    [Abstract] [Full Text] [Related]

  • 8. Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma.
    Undas A, Zubkiewicz-Usnarska L, Helbig G, Woszczyk D, Kozińska J, Dmoszyńska A, Podolak-Dawidziak M, Kuliczkowski K.
    Eur J Clin Invest; 2014 Jun 01; 44(6):557-66. PubMed ID: 24738991
    [Abstract] [Full Text] [Related]

  • 9. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots.
    Carr ME, Alving BM.
    Blood Coagul Fibrinolysis; 1995 Sep 01; 6(6):567-73. PubMed ID: 7578900
    [Abstract] [Full Text] [Related]

  • 10. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
    Jenny L, Noser D, Larsen JB, Dobó J, Gál P, Pál G, Schroeder V.
    Mol Immunol; 2019 Oct 01; 114():1-9. PubMed ID: 31325724
    [Abstract] [Full Text] [Related]

  • 11. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJ, Greenfield RS.
    Int J Mol Med; 2007 Nov 01; 20(5):683-7. PubMed ID: 17912461
    [Abstract] [Full Text] [Related]

  • 12. DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment.
    Varjú I, Longstaff C, Szabó L, Farkas ÁZ, Varga-Szabó VJ, Tanka-Salamon A, Machovich R, Kolev K.
    Thromb Haemost; 2015 Jun 01; 113(6):1289-98. PubMed ID: 25789443
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Fibrin clots obtained from plasma containing heparin show a higher sensitivity to t-PA-induced lysis.
    Nenci GG, Parise P, Morini M, Rossini A, Agnelli G.
    Blood Coagul Fibrinolysis; 1992 Jun 01; 3(3):279-85. PubMed ID: 1643205
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.
    von dem Borne PA, Cox LM, Bouma BN.
    Blood Coagul Fibrinolysis; 2006 Jun 01; 17(4):251-7. PubMed ID: 16651866
    [Abstract] [Full Text] [Related]

  • 17. Biochemical and biophysical conditions for blood clot lysis.
    Šabovič M, Blinc A.
    Pflugers Arch; 2000 Jan 01; 440(Suppl 1):R134-R136. PubMed ID: 28008511
    [Abstract] [Full Text] [Related]

  • 18. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
    Kwasny-Krochin B, Gluszko P, Undas A.
    Thromb Res; 2010 Jul 01; 126(1):e11-6. PubMed ID: 20471669
    [Abstract] [Full Text] [Related]

  • 19. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M, Fil K, Bazanek M, Undas A.
    Thromb Haemost; 2014 Apr 01; 111(4):685-93. PubMed ID: 24306139
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.